A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer’s disease to test IGC-AD1, an investigational cannabis-based treatment being developed India Globalization Capital (IGC) Pharma, a subsidiary of IGC, according to a recent press release. In the placebo-controlled study, 12 participants will receive the medication over three 14-day periods, with the…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden
AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its therapy candidates for Alzheimer’s disease, the company announced. The trial follows the release of the first positive clinical results, in which ACD856 showed a good pharmacokinetic profile (how the body affects…
Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial
Most of the mild to moderate Alzheimer’s patients enrolled in the atuzaginstat (COR388) Phase 2/3 trial show evidence of systemic infection due to Porphyromonas gingivalis, a bacteria linked to periodontal disease whose toxic enzymes are thought to contribute to Alzheimer’s and are targets for this candidate therapy. A “high proportion” also test positive for biomarkers associated with this neurodegenerative disease.…
Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year
The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy AMX0035 in people with Alzheimer’s disease. Top-line results from the trial are expected in the first half of 2021. “The PEGASUS trial design and broad inclusion…
FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients
The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with Alzheimer’s disease. The randomized, double-blinded, placebo-controlled trial is expected to enroll more than 500 people with mild cognitive impairment due to Alzheimer’s disease at more…
FDA Committee Votes Do Not Support Aducanumab as Effective Treatment
An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy in treating Alzheimer’s disease. In votes, eight of the committee’s 11 members found Phase 3 EMERGE data did not provide “strong evidence” of efficacy, and seven members…
EMA Agrees to Review Biogen, Eisai Request for Aducanumab’s Approval
The European Medicines Agency (EMA) has agreed to review Biogen and Eisai’s application requesting the approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease. The companies’ approval request — in the form of a marketing authorization application (MAA) — will be analyzed by the EMA following the usual review timetable for new medications, which can…
Awareness Month Activities Shine Spotlight on Alzheimer’s, Dementia
Efforts are underway this month to focus attention on Alzheimer’s, a disease that, along with other forms of dementia, affects some 44 million people globally and is swiftly growing in prevalence. During November in the U.S., Alzheimer’s Awareness Month observances include fundraisers, disseminating tips for healthy aging, downloadable Alzheimer’s information, “memory walks,” and information and resources for…
Seth Rogen’s HFC ‘Game Show’ Raises $325K to Benefit Alzheimer’s Care
Using levity to battle a serious disease, entertainer Seth Rogen and his wife raised more than $325,000 for HFC, the couple’s national Alzheimer’s disease organization, during its first virtual game show. The funds will help in providing at-home care at no extra charge to Alzheimer’s patients, as well as online support for caregivers. Money will also support brain…
First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801
A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific genetic variant associated with an increased risk of disease progression. “This biomarker study is a key element of our overall Alzheimer’s clinical development program for ALZ‑801,”…
Simple Language Test May Predict Alzheimer’s Onset Years Before Symptoms Start
A simple language test, when combined with an artificial intelligence model, can predict which people will develop Alzheimer’s disease later in life, a study shows. This new model predicted Alzheimer’s seven years before its diagnosis with an accuracy of 70%, according to the study. That rate is higher than those attained by traditional predictive methods,…
RetiSpec and Gentex Developing Technology to Detect Early Alzheimer’s
RetiSpec and Gentex are partnering to develop a technology to detect Alzheimer’s disease — potentially years before symptom onset — using a non-invasive and cost-effective eye scan technique. The partnership between the two companies will expedite the development of the technology, with the goal of bringing it to market to advance patient care. “The Gentex-RetiSpec partnership…